Inhibrx Biosciences (INBX) Return on Sales (2024 - 2025)
Historic Return on Sales for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to 120.31%.
- Inhibrx Biosciences' Return on Sales rose 3772700.0% to 120.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 120.31%, marking a year-over-year increase of 3772700.0%. This contributed to the annual value of 8437.86% for FY2024, which is 85710400.0% up from last year.
- Inhibrx Biosciences' Return on Sales amounted to 120.31% in Q3 2025, which was up 3772700.0% from 22.04% recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Return on Sales peaked at 18580.11% during Q2 2024, and registered a low of 1568.4% during Q2 2023.
- Its 3-year average for Return on Sales is 1590.87%, with a median of 39.16% in 2025.
- Its Return on Sales has fluctuated over the past 5 years, first surged by 201485100bps in 2024, then crashed by -186021500bps in 2025.
- Over the past 3 years, Inhibrx Biosciences' Return on Sales (Quarter) stood at 56.29% in 2023, then tumbled by -750bps to 478.65% in 2024, then surged by 125bps to 120.31% in 2025.
- Its last three reported values are 120.31% in Q3 2025, 22.04% for Q2 2025, and 16.11% during Q1 2025.